Jean Pierre Gafaranga

Dr. Jean Pierre Gafaranga

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
JGJean Pierre Gafaranga
Jean Pierre Gafaranga
FMFelix MANIRAKIZA
Felix MANIRAKIZA
ENEmmanuel Ndagijimana
Emmanuel Ndagijimana
JUJean Christian Urimubabo
Jean Christian Urimubabo
IKIrénée David Karenzi
Irénée David Karenzi
BRBelson Rugwizangoga
Belson Rugwizangoga
Background: Cervical cancer is a global public health problem with marked geographical disparity. High morbidity and mortality rates in developing countries are associated with low screening rates. In 2020, in Rwanda, 3.7 million women aged 15– 59 years were at risk of developing cervical cancer, the most commonly diagnosed female cancer in Rwanda. Despite Rwanda being the first African country to vaccinate against human papilloma virus with a three-dose regimen vaccination coverage of nearly 93% in the target population of girls aged < 15 years, and having established cervical cancer screening program, recent studies have found low screening rates. Our study sought to determine knowledge, motivators and barriers of cervical cancer screening. Methods: We conducted a qualitative descriptive study; using focus group interview in an urban health facility (Muhima district hospital) and a rural health center (Nyagasambu health center) offering cervical screening services in Rwanda. Participants were women seeking these services and other women attending the health facility for any reason, and female staff working in these facilities. Interviews were recorded and transcribed, and data were analyzed using content analysis. Results: Thirty women participated in focus group interview, with an average age of 39 years. Many of women showed knowledge about cervical cancer existence and prevention methods. However, fear for pain, lack of knowledge about screening, how and where the screening was done, and concern for privacy were recurring subthemes. Some participants also mentioned lack of health insurance as a barrier for cervical cancer screening. Conclusion: Barriers to uptake cervical cancer screening services in Rwanda are related to poor information about cervical cancer and the importance of screening as well as non-adherence to medical insurance. Population sensitization through campaign and community outreach activities could have a positive impact on increasing the usage of cervical cancer screening in Rwanda.

1 April 2024 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
JGJean Pierre Gafaranga
Jean Pierre Gafaranga
LBLeopold Bitunguhari
Leopold Bitunguhari
CMCharles Mudenge
Charles Mudenge
FMFelix MANIRAKIZA
Felix MANIRAKIZA
BKBrian Kelly
Brian Kelly
PGPaul Gatabazi
Paul Gatabazi
Background: Depression is a significant global public health concern, affecting individuals across different age groups and cultural backgrounds. However, screening for depression remains an essential but often neglected aspect of healthcare, particularly in outpatient settings. This study aimed to assess the prevalence of depression among outpatients visiting the internal medicine department of the University Teaching Hospital of Kigali in Rwanda and evaluate the feasibility of implementing a depression screening program in this setting. Methods: An institution-based cross-sectional study design was employed, involving 300 adult medical outpatients through convenience sampling, aged 18 years and above, who visited the internal medicine department between October 7 to November 6, 2019. The Patient Health Questionnaire-9 (PHQ-9) was used as the screening tool to assess depressive symptoms. Additionally, socio-demographic and clinical data were collected to explore potential risk factors associated with depression using a binary logistic regression model. Results: A high prevalence of depression was identified among internal medicine outpatients, with 45.7% of participants screened positive for depression, with moderate, moderately severe, and severe depression accounting for 21%, 17%, and 8%, respectively. The following factors were significantly associated with positive screening for depression: lack of formal education (OR=4.463, p=0.011, 95% CI= [1.410; 14.127]), secondary education (OR=3.402, p=0.003, 95% CI= [1.517; 7.630]), low-income (OR=2.392, p=0.049, 95% CI= [1.003; 5.706]) and headache as a chief complaint (OR=3.611, p=0.001, CI= [1.718; 7.591]). Conclusion: This study highlights the high prevalence of depression among medical outpatients. Due to the stigma associated with mental health, patients frequently seek help for physical symptoms such as headaches and other bodily complaints rather than mental health concerns. Introducing routine depression screening in medical departments could potentially facilitate early identification, and intervention, and lead to improved patient care. Future research should focus on evaluating such screening programs’ effectiveness and long-term outcomes in resource-limited settings like Rwanda.

27 September 2021 in Research Square
Verified
Preprint
Open access
PDF file
JGJean Pierre Gafaranga
Jean Pierre Gafaranga
FMFelix Manirakiza
Felix Manirakiza
ENEmmanuel Ndagijimana
Emmanuel Ndagijimana
JUJean Christian Ulimubabo
Jean Christian Ulimubabo
DKDavid Irenée Karenzi
David Irenée Karenzi
BRBelson Rugwizangoga
Belson Rugwizangoga
Background: Cervical cancer is a global public health problem with marked geographical disparity. There are high morbidity and mortality rates in low- and middle-income countries (LMICs) associated with low screening rates. In 2020, in Rwanda, 3.7 million women aged 15–59 years were at risk of developing cervical cancer. It is the most commonly diagnosed female cancer in Rwanda with an incidence rate of 42 cases per 100,000 women per year. Despite Rwanda being the first African country to vaccinate against human papillomavirus (HPV) with a three-dose regimen, vaccination coverage of nearly 93 % in the target population of girls aged < 15 years, and having an established cervical cancer screening program, recent studies have found low screening rates. Our study sought to determine knowledge, motivators, and barriers to cervical cancer screening.Methods: This was a qualitative phenomenological study conducted in an urban health facility (Muhima district hospital) and a rural health center (Nyagasambu health center) offering cervical screening services in Rwanda. Focus group discussion (FGD) participants were women seeking these services and other women attending the health facility for any reason, as well as female staff working in these health centers. We also interviewed a key informant (KI) from the national organization. FGD and KI interviews were recorded and transcribed, and the data were analyzed using thematic analysis.Results: Thirty women were enrolled in the FGDs, with an average age of 39 years. Many FGD women showed knowledge about cervical cancer existence and prevention methods. However, fear for pain, lack of knowledge about screening, how and where the screening was done, and privacy concerns were recurring subthemes. Key-informant and some FGDs participants have also mentioned a lack of health insurance as a possible barrier for cervical cancer screening.Conclusions: Barriers to the utilization of cervical cancer screening program in Rwanda are related to poor information about cervical cancer and the importance of screening among women, as well non-adherence to medical insurance schemes. Population sensitization through campaign and community outreach activities could have a positive impact on increasing the uptake of cervical cancer screening in Rwanda.

1 October 2023 in International Medical Case Reports Journal
Verified
Journal Article
Open access
PDF file
JGJean Pierre Gafaranga
Jean Pierre Gafaranga
This report presents a case study of a patient who experienced depression and panic disorder symptoms associated with the use of Implanon, a contraceptive implant. This is a rare case of related prevalence data. The purpose of this report is to explore the potential relationship between Implanon and the development of these psychiatric conditions. The findings suggest a possible link between Implanon and the onset or exacerbation of depression and panic disorder symptoms. Further research is warranted to investigate the underlying mechanisms and determine the prevalence of such adverse effects.

1 October 2026 in International Medical Case Reports Journal
Verified
Journal Article
Open access
PDF file
MGMelissa Lowan Gihozo
Melissa Lowan Gihozo
JGJean Pierre Gafaranga
Jean Pierre Gafaranga
Excessive yawning is an uncommon but recognized adverse effect of selective serotonin reuptake inhibitors (SSRIs). Although generally benign, it may cause distress and may be mistaken for a symptom of psychiatric or neurological illness. Case reports and pharmacovigilance data have linked escitalopram to yawning, sometimes in a dose-dependent manner. To our knowledge, this is one of the first reported cases of escitalopram-associated yawning in Rwanda. We describe a 44-year-old woman from rural Rwanda who presented with a severe depressive episode and comorbid post-traumatic stress disorder (PTSD). Three days after starting escitalopram 10 mg daily, she reported markedly increased yawning, approximately six episodes every 15 minutes throughout the day, while her sleep and mood had begun to improve slightly. Medical and neurological causes, sleep-related causes and concurrent short-term diazepam use were considered and judged unlikely. The Naranjo Adverse Drug Reaction Probability Scale score was 5, indicating a probable adverse drug reaction. Escitalopram was continued because of emerging antidepressant benefit, and the yawning had decreased substantially at the two-week follow-up. This case suggests that yawning occurring early in escitalopram treatment should be recognized as a probable adverse drug reaction. Awareness of this under-reported effect may prevent unnecessary investigations and premature discontinuation of an effective antidepressant.

8 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
GDGayathri Delanerolle
Gayathri Delanerolle
IAIeera Aggarwal
Ieera Aggarwal
Vindya PathirajaVindya Pathiraja
Vindya Pathiraja
George Uchenna ElejeGeorge Uchenna Eleje
George Uchenna Eleje
TTTeck-Hock Toh
Teck-Hock Toh
PPPeter Phiri
Peter Phiri
Background: Menopause affects more than one billion individuals worldwide, yet outcome measurement in research remains narrow, inconsistent, and largely focused on vasomotor and genitourinary symptoms. Existing frameworks do not adequately capture the broader functional and psychosocial impacts reported by patients. We aimed to develop and validate a global Core Patient-Reported Outcome Set for Menopause (cPRO-MARiE) using prospective mixed-methods data from thirteen countries. Methods: We analysed quantitative data from 5,228 participants and qualitative interviews from 302 individuals across thirteen countries spanning diverse socio-cultural and health-system contexts. Validated instruments assessed symptom severity, psychological wellbeing, cognitive function, sleep disturbance, pain and somatic symptoms, and functional outcomes. Qualitative data underwent reflexive thematic analysis guided by the Delanerolle–Phiri framework. A COMET-aligned process integrating quantitative severity patterns, qualitative thematic convergence, cross-country reproducibility, psychometric validation and equity considerations was applied to derive the core outcome set. Findings: Seven domains were consistently identified across all settings: sleep disturbance; psychological wellbeing; cognitive function; pain and somatic symptoms; vasomotor symptoms; genitourinary and sexual health; and social, relational and occupational functioning. These domains demonstrated conceptual stability, cross-country reproducibility and psychometric coherence and were strongly linked to functional impact. The resulting cPRO-MARiE specifies mandatory Tier 1 patient-reported outcomes within each domain, with Tier 2 outcomes retained for context-specific and equity-focused research. Interpretation: cPRO-MARiE is the first empirically derived, globally validated core outcome set for menopause. By capturing symptom domains and functional impacts prioritised by patients across diverse settings, it provides a robust and clinically meaningful framework for outcome measurement in research, routine care, and health-system evaluation.